Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 3:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 33,061 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo Clear all
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant

NCT02988115
View directory record Official record
Conditions
Hypercholesterolemia, Atherosclerotic Cardiovascular Disease, Statin Adverse Reaction
Interventions
bempedoic acid, placebo
Drug · Other
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
52
States / cities
Gilbert, Arizona • Anaheim, California • Long Beach, California + 47 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 18, 2026, 3:30 AM EDT
Completed Not applicable Interventional

Study of the Carbon Dioxide Treatment for Fat Reduction

NCT00974415
View directory record Official record
Conditions
Overweight
Interventions
CO2, Sham
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 18, 2026, 3:30 AM EDT
Not listed Phase 2 Interventional

LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC

NCT04759664
View directory record Official record
Conditions
EGFRI Induced Acneiform Lesions
Interventions
LUT014 Gel (Dose 1), LUT014 Gel (Dose 2), Placebo
Drug
Lead sponsor
Lutris Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
17
States / cities
Glendale, California • Santa Monica, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Oct 18, 2026, 3:30 AM EDT
Terminated Phase 2 Interventional Results available

Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE)

NCT02992132
View directory record Official record
Conditions
Agitation and Aggression in Alzheimer's Disease
Interventions
Pimavanserin 34 mg, Pimavanserin 20 mg, Placebo
Drug · Other
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
50 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
33
States / cities
Costa Mesa, California • Fresno, California • Fullerton, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Oct 18, 2026, 3:30 AM EDT
Terminated Phase 2 Interventional Results available

Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets

NCT04899921
View directory record Official record
Conditions
Melanoma, Metastatic Melanoma
Interventions
Ipilimumab, Nivolumab, Troriluzole, Placebo
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 18, 2026, 3:30 AM EDT
Withdrawn Phase 4 Interventional

Anti-suicidal Effects of Buprenorphine in Opioid Use Disorder

NCT04234516
View directory record Official record
Conditions
Opioid-use Disorder, Suicidal Ideation
Interventions
Buprenorphine/Naloxone 8/2 milligram (mg) Sublingual Film, Morphine Sulfate 30 mg
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 18, 2026, 3:30 AM EDT
Recruiting Phase 4 Interventional

A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)

NCT06785116
View directory record Official record
Conditions
Gestational Hypertension, Hypertension in Pregnancy, Pre-Eclampsia, Superimposed Pre-Eclampsia, Cardiovascular Complication
Interventions
Placebo, Dapagliflozin 10mg Tab
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 18, 2026, 3:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Mirtazapine and Methamphetamine Drug-drug Interaction Study

NCT04614584
View directory record Official record
Conditions
Methamphetamine Use Disorder, Drug Interaction, Cardiovascular Abnormalities
Interventions
Mirtazapine, Methamphetamine
Drug
Lead sponsor
San Francisco Department of Public Health
Government
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
3
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 27, 2024 · Synced Oct 18, 2026, 3:30 AM EDT
Completed Phase 4 Interventional Results available

Stress Neuroadaptation in Tobacco Dependence

NCT03262233
View directory record Official record
Conditions
Nicotine Dependence
Interventions
nicotine, placebo
Combination Product · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 60 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 18, 2026, 3:30 AM EDT
Completed Phase 2 Interventional Results available

BI 671800 in Asthmatic Patients on Inhaled Corticosteroids

NCT01103349
View directory record Official record
Conditions
Asthma
Interventions
BI 671800, Placebo, Montelukast
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
6
States / cities
Denver, Colorado • North Dartmouth, Massachusetts • Plymouth, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Oct 18, 2026, 3:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Monosodium Glutamate on Energy Balance and Eating Behavior

NCT01410838
View directory record Official record
Conditions
Obesity, Weight Gain, Food Preferences
Interventions
Broth
Other
Lead sponsor
USDA, Western Human Nutrition Research Center
Federal
Eligibility
19 Years to 50 Years · Female only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Oct 18, 2026, 3:30 AM EDT
Completed Phase 2 Interventional

A Phase II Study in Patients With Moderate to Severe Active Crohn's Disease

NCT03677648
View directory record Official record
Conditions
Crohn's Disease
Interventions
SHR0302, Placebos
Drug
Lead sponsor
Reistone Biopharma Company Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
6
States / cities
Clearwater, Florida • Lake Wales, Florida • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 18, 2026, 3:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Radicle Calm 1: A Study of Health and Wellness Products on Feelings of Anxiety, Stress and Other Health Outcomes

NCT05589948
View directory record Official record
Conditions
Anxiety, Stress
Interventions
Radicle Calm Study Placebo Control 1, Radicle Calm Study Placebo Control 2, Radicle Calm Study Active Product 1.1, Radicle Calm Study Active Product 2.1, Radicle Calm Study Active Product 2.2
Dietary Supplement
Lead sponsor
Radicle Science
Industry
Eligibility
21 Years to 105 Years
Enrollment
1,211 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Del Mar, California
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 18, 2026, 3:30 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)

NCT05686408
View directory record Official record
Conditions
Depression, Depressive Disorder, Depressive Symptoms, Depressive Disorder, Major, Depressive Episode, Depression Severe
Interventions
TNX-601 ER, Placebo
Drug
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
27
States / cities
Little Rock, Arkansas • Bellflower, California • Glendale, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Oct 18, 2026, 3:30 AM EDT
Withdrawn Not applicable Interventional

Effect of Cranberry Extract on Infections in Burn Patients

NCT01225107
View directory record Official record
Conditions
Burn
Interventions
Cranberry Extract, Inert Placebo Capsule
Dietary Supplement · Drug
Lead sponsor
Saint Elizabeth Regional Medical Center
Other
Eligibility
19 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 13, 2016 · Synced Oct 18, 2026, 3:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of MGD010 in Healthy Subjects

NCT02376036
View directory record Official record
Conditions
Healthy Subjects
Interventions
MGD010, Placebo, Hepatitis A vaccine
Drug · Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years to 50 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 18, 2026, 3:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Decision Making Study in Young and Middle-Aged Adults: Part II

NCT03512171
View directory record Official record
Conditions
Healthy Adults
Interventions
Dextroamphetamine, Placebo, [18F]Fallypride, [18F]-FE-PE2I
Drug · Diagnostic Test
Lead sponsor
Vanderbilt University
Other
Eligibility
20 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Oct 18, 2026, 3:30 AM EDT
Active, not recruiting Phase 3 Interventional

LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2

NCT07288398
View directory record Official record
Conditions
Pulmonary Hypertension Associated With HFpEF
Interventions
TNX-103, Placebo
Drug
Lead sponsor
Tenax Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
45
States / cities
Alexander City, Alabama • Tucson, Arizona • Sacramento, California + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 18, 2026, 3:30 AM EDT
Completed Phase 2 Interventional Results available

Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas

NCT01433263
View directory record Official record
Conditions
Cachexia
Interventions
BYM338 active drug, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
6
States / cities
Tucson, Arizona • Tampa, Florida • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Oct 18, 2026, 3:30 AM EDT
Recruiting Phase 3 Interventional

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

NCT06528314
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions
Efruxifermin, Placebo
Drug
Lead sponsor
Akero Therapeutics, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
2,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
169
States / cities
Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 141 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 18, 2026, 3:30 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1)

NCT03927716
View directory record Official record
Conditions
Molluscum Contagiosum
Interventions
SB206 12%, Placebo
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
6 Months and older
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
35
States / cities
Mobile, Alabama • Glendale, Arizona • Little Rock, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Oct 18, 2026, 3:30 AM EDT
Completed Not applicable Interventional Results available

Dalfampridine and Gait in Spinocerebellar Ataxias

NCT01811706
View directory record Official record
Conditions
Spinocerebellar Ataxias Type 1, Spinocerebellar Ataxias Type 2, Spinocerebellar Ataxias Type 3, Spinocerebellar Ataxias Type 6
Interventions
Dalfampridine, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 12, 2015 · Synced Oct 18, 2026, 3:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Placebo Controlled Study of Atomoxetine in the Treatment of Mild to Moderate Cognitive Difficulties in Menopausal Women

NCT00611533
View directory record Official record
Conditions
Menopause, Cognitive Disturbances
Interventions
atomoxetine, placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 18, 2026, 3:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Herbal Products on Metabolism and Hunger

NCT00198952
View directory record Official record
Conditions
Obesity, Metabolism
Interventions
DietPro, Placebo
Drug
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2001
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 20, 2005 · Synced Oct 18, 2026, 3:30 AM EDT